EUCTR2010-024247-32-BE进行中（未招募）1 期
A PHASE 2, RANDOMIZED, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND ANTI-CYTOMEGALOVIRUS (CMV) ACTIVITY OF MARIBAVIR VERSUS VALGANCICLOVIR FOR TREATMENT OF CMV INFECTIONS IN TRANSPLANT RECIPIENTS WHO DO NOT HAVE CMV ORGAN DISEASE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Be =18 years of age.
- •2. Be a recipient of stem cell or solid organ transplantation.
- •3. Have documented CMV infection in blood or plasma, with a screening value of =1,000 to =100,000 DNA copies/mL as determined by quantitative PCR or comparable quantitative CMV assay type. Results from either the central laboratory or a local laboratory can be used for qualification.
- •4. Have CMV infection that does not meet the definition of CMV organ disease at the time of enrollment (see Appendix IV).
- •5. Have a CMV infection that is not known to be resistant to ganciclovir/valganciclovir, foscarnet, or cidofovir based on genotypic evidence.
- •6. Have all of the following findings as part of screening laboratory assessment (results from either the central laboratory or a local laboratory can be used for qualification):
- •Absolute neutrophil count (ANC =500/mm3 [0.5 x 109/L]
- •Platelet count =25,000/mm3 [25 x 109/L]
- •Hemoglobin =8 g/dL
- •7. If female, be either postmenopausal, surgically sterile, or have a negative pregnancy test as part of screening laboratory assessments (pregnancy test results from either the central laboratory or a local laboratory can be used for qualification). Women of child bearing potential also must agree to use an acceptable method of birth control, as determined by the investigator, during the study drug administration period and for 3 months afterward. Hormonal contraceptives should not be used as the sole method of birth control.
- •If male, must agree to use an acceptable method of birth control, as determined by
- •the investigator, during the study drug administration period and for 3 months afterward.
- •8. Be able to swallow tablets.
- •9. Be informed of the nature of the study and provide written informed consent
- •before any study-specific procedures are performed. [NOTE: Subjects must be
- •fully able to give their consent.]
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 144
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •Subjects must not:
- •1. Be receiving any of the following therapies when study drug is initiated:
- •ganciclovir
- •valganciclovir
- •foscarnet
- •cidofovir
- •CMV immune globulin (CMV-IGIV, Cytogam®)
- •leflunomide
- •artesunate
- •NOTE: A subject may have received any of the above listed drugs prior to enrollment. If this is the case, these drugs must be discontinued, and a washout” period of =24 hours is required between the last dose and commencement of dosing with study drug.
- •2. Have known allergies to one of the study medications (e.g., valganciclovir) or its excipients.
- •3. Have estimated creatinine clearance (CrCl) <10 mL/min or require dialysis when
- •study drug is initiated.
- •4. Have severe vomiting, diarrhea, or other severe gastrointestinal illness within 24 hours prior to the first dose of study drug that would preclude administration of oral/enteral medication.
- •5. Require mechanical ventilation or vasopressors for hemodynamic support at the time of enrollment.
- •6. Have any serious illness with expected survival less than 6 weeks.
- •7. Be pregnant (as determined by ß-human chorionic gonadotropin testing prior to
- •initiation of study drug) or breastfeeding.
- •8. Have received any investigational (unapproved) agent with known anti-CMV
- •activity within 30 days before initiation of study drug.
- •9. Have any clinically significant medical or surgical condition that in the investigator’s or sponsor’s opinion could interfere with the administration of study drug or interpretation of study results, or compromise the safety or wellbeing of the subject.
研究者
相似试验
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsCMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 17.0Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862MedDRA version: 17.0Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862EUCTR2010-024247-32-GBShire ViroPharma Incorporated160
进行中（未招募）
不适用
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patients.CMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 15.1Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 100000004862MedDRA version: 15.1Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 100000004862EUCTR2010-024247-32-ESVIROPHARMA INCORPORATED160
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsEUCTR2010-024247-32-DEVIROPHARMA INCORPORATED159
进行中（未招募）
不适用
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsCMV INFECTIONS IN TRANSPLANT RECIPIENTSMedDRA version: 14.1Level: LLTClassification code 10021819Term: Infection in marrow transplant recipientsSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10021829Term: Infection in solid organ transplant recipientsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-024247-32-FRVIROPHARMA INCORPORATED160
进行中（未招募）
1 期
A study to determine how safe and effective maribavir versus Valganciclovir is in treating cytomegalovirus(CMV) in transplant patientsEUCTR2010-024247-32-ATSHIRE VIROPHARMA INCORPORATED159